Document is current
Any future updates will be listed below
-
Authors
Gaetani, Lorenzo
Bellomo, Giovanni
Nardi, Giovanna
Toja, Andrea
Streva, Carla
Giombetti, Erica
Torrigiani, Edoardo Guido
Paolini Paoletti, Federico
Villa, Alfredo
Tozzi, Alessandro
Chiasserini, Davide
Parnetti, Lucilla
-
Funding
Funding for this research was provided by:
Associazione Italiana Ricerca Alzheimer
Parkinson's Foundation
Ministero dell'Università e della Ricerca
- License Information
-
More Information
Article History
Received: 1 November 2025
Accepted: 21 January 2026
First Online: 2 February 2026
Declarations
:
: L. Gaetani has participated in advisory boards for and received writing or speaker honoraria and travel grants from Almirall, Biogen, Eisai, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. G. Bellomo received honoraria from Fujirebio and completed paid consultancies for Parkinson’s Foundation. He received travel/educational grants from Fujirebio and Alzheimer’s Association. D. Chiasserini has nothing to disclose. L. Parnetti served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck.
